CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.
A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.
Shares of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) were trading at $1.65, down $2.45, or 59%, after the company disclosed phase II results from the Bestow trial testing tegoprubart, which targets ...
In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral ...
New information to be presented on the study design and methodology of Purespring’s Phase I/IItrial of PS-002, an AAV-based therapy delivering ...
GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...
Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board ...
Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of ...
Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...
Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® - Q3 2025 operating profit of €11.0 million - TransCon® CNP (navepegritide) under FDA Priority Review for the ...
Nearly two years ago, Chad Gluss went into cardiac arrest and wound up needing a heart transplant. In January, he will be ...
Health Technology Wales has recommended a digital rehabilitation and self-management platform for people living with chronic kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback